FDA Rejects Unicycive's Drug for Dialysis Patients

The FDA has declined to approve a drug intended to manage elevated phosphate levels in dialysis patients, citing manufacturing deficiencies. While the drug's safety and efficacy were not questioned, this decision highlights ongoing challenges in the pharmaceutical industry regarding quality control and regulatory compliance.